341 related articles for article (PubMed ID: 16650406)
1. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator.
Radosevich M; Jager M; Ono SJ
Exp Mol Pathol; 2007 Feb; 82(1):68-76. PubMed ID: 16650406
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
4. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines.
Goodwin BL; Xi H; Tejiram R; Eason DD; Ghosh N; Wright KL; Nagarajan U; Boss JM; Blanck G
Cell Growth Differ; 2001 Jun; 12(6):327-35. PubMed ID: 11432807
[TBL] [Abstract][Full Text] [Related]
5. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
6. Constitutive and IFNgamma-induced activation of MHC2TA promoter type III in human melanoma cell lines is governed by separate regulatory elements within the PIII upstream regulatory region.
van der Stoep N; Quinten E; Alblas G; Plancke A; van Eggermond MC; Holling TM; van den Elsen PJ
Mol Immunol; 2007 Mar; 44(8):2036-46. PubMed ID: 17067677
[TBL] [Abstract][Full Text] [Related]
7. IFN-gamma regulation of the type IV class II transactivator promoter in astrocytes.
Dong Y; Rohn WM; Benveniste EN
J Immunol; 1999 Apr; 162(8):4731-9. PubMed ID: 10202014
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA).
Takamura Y; Ikeda H; Kanaseki T; Toyota M; Tokino T; Imai K; Houkin K; Sato N
Glia; 2004 Mar; 45(4):392-405. PubMed ID: 14966870
[TBL] [Abstract][Full Text] [Related]
9. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells.
Croce M; De Ambrosis A; Corrias MV; Pistoia V; Occhino M; Meazza R; Giron-Michel J; Azzarone B; Accolla RS; Ferrini S
Oncogene; 2003 Oct; 22(49):7848-57. PubMed ID: 14586411
[TBL] [Abstract][Full Text] [Related]
10. Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells.
Rigaud G; De Lerma Barbaro A; Nicolis M; Cestari T; Ramarli D; Riviera AP; Accolla RS
J Immunol; 1996 Jun; 156(11):4254-8. PubMed ID: 8666795
[TBL] [Abstract][Full Text] [Related]
11. Identification of distinct regions of 5' flanking DNA that mediate constitutive, IFN-gamma, STAT1, and TGF-beta-regulated expression of the class II transactivator gene.
Piskurich JF; Wang Y; Linhoff MW; White LC; Ting JP
J Immunol; 1998 Jan; 160(1):233-40. PubMed ID: 9551976
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-induced MHC class II gene expression is suppressed in endothelial cells by dextran sulfate.
Lian RH; Kotwal GJ; Wellhausen SR; Hunt LA; Justus DE
J Immunol; 1996 Jul; 157(2):864-73. PubMed ID: 8752940
[TBL] [Abstract][Full Text] [Related]
13. Collagen and major histocompatibility class II expression in mesenchymal cells from CIITA hypomorphic mice.
Xu Y; McDonald J; Perloff E; Butticè G; Schreiber BM; Smith BD
Mol Immunol; 2007 Mar; 44(7):1709-21. PubMed ID: 16982097
[TBL] [Abstract][Full Text] [Related]
14. Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.
Sartoris S; Tosi G; De Lerma Barbaro A; Cestari T; Accolla RS
Eur J Immunol; 1996 Oct; 26(10):2456-60. PubMed ID: 8898960
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
16. A CIITA-independent pathway that promotes expression of endogenous rather than exogenous peptides in immune-privileged sites.
Arancibia-Cárcamo CV; Osawa H; Arnett HA; Háskova Z; George AJ; Ono SJ; Ting JP; Streilein JW
Eur J Immunol; 2004 Feb; 34(2):471-80. PubMed ID: 14768052
[TBL] [Abstract][Full Text] [Related]
17. CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
Meissner M; Whiteside TL; Kaufmann R; Seliger B
Arch Dermatol Res; 2009 Feb; 301(2):189-93. PubMed ID: 19104823
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression.
Lee YJ; Han Y; Lu HT; Nguyen V; Qin H; Howe PH; Hocevar BA; Boss JM; Ransohoff RM; Benveniste EN
J Immunol; 1997 Mar; 158(5):2065-75. PubMed ID: 9036950
[TBL] [Abstract][Full Text] [Related]
19. CIITA transformation rescues the apoptotic function of MHC class II in melanoma cells.
Le E; Zhang H; Blanck G
Anticancer Res; 2005; 25(6B):3889-92. PubMed ID: 16312044
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells.
Morimoto Y; Toyota M; Satoh A; Murai M; Mita H; Suzuki H; Takamura Y; Ikeda H; Ishida T; Sato N; Tokino T; Imai K
Br J Cancer; 2004 Feb; 90(4):844-52. PubMed ID: 14970863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
